bhv-0223
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03017508)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bhv-0223
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03520517 | Phase 1 | Feb 2, 2018 | Biohaven Pharmaceuticals Inc., Cognitive Research Corporation |
| NCT03017508 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2017 | Biohaven Pharmaceuticals Inc., Yale University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals Inc. | For profit | 2 | 1 | 2 | 2017 |
| Cognitive Research Corporation | For profit | 1 | 0 | 1 | 2018 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1